Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)

NCT07473232 | Not Yet Recruiting DMC

• 2 other identifiers: E-60116787-020- 615862025TIPF037
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared

Conditions

Knee Arthritis Osteoarthritis; Platelet Rich Plasma Injection; Conditioned Serum

Keywords

knee osteoarthritis; platelet rich plasma injection; conditioned serum injection; inflammation; cartilage

Outcome Measures

Primary Outcomes (1)

• Visual pain scale score

  Visual pain scale score (min 0-max 10), higher scores indicate better results

  Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection.

Study Arms (2)

PRP group

EXPERIMENTAL

patients with knee osteoarthritis who will be injected with autologous PRP

Drug: Autologous Platelet-Rich Plasma (PRP)

conditioned serum group

EXPERIMENTAL

patients with knee osteoarthritis who will be injected with autologous conditioned serum

Drug: Conditioned serum (CS)

Interventions

Autologous Platelet-Rich Plasma (PRP) DRUG

Autologous Platelet-Rich Plasma (PRP) will be injected intra-articularly in patients with knee osteoarthritis

PRP group

Conditioned serum (CS) DRUG

Autologous conditionedserum (CS) will be injected intra-articularly in patients with knee osteoarthritis

conditioned serum group

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
• Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
• Not having had PRP injection in the last year.
• Knee pain ≥ 5 according to the visual pain scale.

You may not qualify if:

• Those with significant neurological or cardiovascular disorders.
• Those with active thrombovascular disease.
• Those with joint or skin infections.
• Those who have recently had an infectious disease.
• Those infected with Hepatitis B, C, and HIV.
• Those who have received intra-articular knee injections (hyaluronic acid, PRP, corticosteroids, and others) within the last year.
• Those who use oral corticosteroids.
• Those who have used NSAIDs within the last week.
• Those who have used anti-platelet or anti-aggregant drugs within the last week.
• Those with coagulation disorders.
• Those with hemoglobin \<10 g/dl and platelet count \<100,000
• Those with cancer.
• Pregnant or breastfeeding women, drug addicts.
• Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.
• Those with diseases causing secondary osteoarthritis:

Sponsors & Collaborators

• Pamukkale University: lead

MeSH Terms

Conditions

Osteoarthritis, Knee; Inflammation

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

GÜLİN FINDIKOĞLU, Professor, MD, PhD

CONTACT

+905334227076; gulin_dr@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PROFESSOR GULIN FINDIKOGLU MD, PhD

Model Details: parallel, randomized, single blinded

Study Record Dates

• First Submitted: March 10, 2026
• First Posted: March 16, 2026
• Study Start: April 1, 2026
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD will be shared until 3 years after the publication.
• Access Criteria: Researchers will be able to access upon personel caontavt by e-mail of the primary investgator.